Therefore, based on the above research part, the CMap small molecule drug analysis was performed using co-expressed genes positively and negatively associated with ARRDC2, and finally two small molecule compounds with potential therapeutic effects on ovarian cancer were predicted: Mercaptopurine and Apigenin (Figure 7). Here, ARRDC2 is linked to ovarian carcinoma.